pimavanserin tartrate + placebo

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Parkinson's Disease Psychosis

Conditions

Parkinson's Disease Psychosis

Trial Timeline

Jul 1, 2010 → Nov 1, 2012

NCT ID

NCT01174004

About pimavanserin tartrate + placebo

pimavanserin tartrate + placebo is a phase 3 stage product being developed by Acadia Pharmaceuticals for Parkinson's Disease Psychosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01174004. Target conditions include Parkinson's Disease Psychosis.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson's Disease Psychosis were approved

Approved (20) Terminated (3) Active (0)

✅Lemborexant + placeboEisaiApproved

✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved

✅Carbidopa/levodopa/entacaponeNovartisApproved

✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

✅carbidopa/levodopa + Carbidopa/Levodopa/EntacaponeNovartisApproved

✅carbidopa, levodopa, entacaponeNovartisApproved

✅Levodopa/carbidopa/entacapone + Levodopa/carbidopaNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02035553	Phase 2	Completed	Nov 1, 2013	Oct 27, 2016	Alzheimer's Disease Psychosis
NCT01174004	Phase 3	Completed	Jul 1, 2010	Nov 1, 2012	Parkinson's Disease Psychosis

Competing Products

20 competing products in Parkinson's Disease Psychosis

See all competitors

Product	Company	Stage	Hype Score
UB-312 + Placebo	Vaxxinity	Phase 1	19
NAV5001 + DaTscan	Navidea Biopharmaceuticals	Phase 3	22
piclozotan + 0.9% sodium chloride (normal saline)	Daiichi Sankyo	Phase 2	35
E2007	Eisai	Phase 3	32
ARICEPT	Eisai	Phase 3	40
Perampanel	Eisai	Phase 3	32
GPI 1485	Eisai	Phase 2	35
E2007	Eisai	Phase 3	40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo	Eisai	Phase 3	40
perampanel + placebo	Eisai	Phase 2	27
Lemborexant + placebo	Eisai	Approved	50
Placebo + E2007 + E2007	Eisai	Phase 3	32
E2007 + E2007 + E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	27
E2007	Eisai	Phase 2	27
2 mg perampanel + 4 mg perampanel + placebo comparator	Eisai	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 2	35
Istradefylline 20 mg or 40 mg	Kyowa Kirin	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 3	40